{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:37Z","timestamp":1794018577714,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.critrevonc.2021.103453","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T11:37:16Z","timestamp":1630064236000},"page":"103453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rethinking mechanisms of neurotoxicity with BCMA directed therapy"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakariya","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-2135","authenticated-orcid":false,"given":"Katherine E.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103453_bib0005","series-title":"Allen Human Brain Atlas","author":"Allen Human Brain Atlas","year":"2010"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0010","first-page":"136","article-title":"An anti-BCMA CAR T-cell therapy (C-CAR088) shows promising safety and efficacy profile in relapsed or refractory multiple myeloma","author":"An","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0015","series-title":"A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody","author":"Anon","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0020","series-title":"Pfizer Halts BCMA Trial Amid Safety Woes","author":"BCMA","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0025","series-title":"AstraZeneca Drops BCMA Drug After Seeing Early Clinical Data","author":"BCMA","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0030","first-page":"134","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy","author":"Berdeja","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2021.103453_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: a phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103453_bib0040","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an Anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"40","key":"10.1016\/j.critrevonc.2021.103453_bib0045","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103453_bib0050","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0055","first-page":"136","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with Relapsed\/Refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0060","first-page":"134","article-title":"Efficacy and safety of fully human bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0070","series-title":"FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma","author":"FDA","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0075","series-title":"FDA Approval of Ide-cel","author":"FDA","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0080","series-title":"FDA Package Insert for ABECMA","author":"FDA","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0085","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2019-127608","article-title":"Efficacy and safety of CAR-T therapy with safety switch targeting BCMA for patients with relapsed\/refractory multiple myeloma in a phase 1 clinical study","volume":"134","author":"Fu","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103453_bib0090","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2021.103453_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131515","article-title":"Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma","volume":"134","author":"Garfall","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103453_bib0100","article-title":"Updated phase 1 results of Teclistamab, a B-Cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0105","first-page":"132","article-title":"Targeted chimeric antigen receptor t cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103453_bib0110","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103453_bib0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000927","article-title":"Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus","volume":"8","author":"Han","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2021.103453_bib0125","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130341","article-title":"Potent anti-tumor activity of BCMA CAR-T therapy against heavily treated multiple myeloma and dynamics of immune cell subsets using single-cell mass cytometry","volume":"134","author":"Hu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0130","first-page":"136","article-title":"Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma","author":"Jiang","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2021.103453_bib0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126104","article-title":"Phase 1 trial of the safety and efficacy of fully human anti-bcma car T cells in relapsed\/refractory multiple myeloma","volume":"134","author":"Jie","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-Human study of MEDI2228, a BCMA-Targeted ADC in patients with Relapsed\/Refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0145","first-page":"136","article-title":"Results from Lummicar-2: a phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma","author":"Kumar","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103453_bib0150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103453_bib0155","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fnsys.2014.00016","article-title":"Cognitive-motor interactions of the basal ganglia in development","volume":"8","author":"Leisman","year":"2014","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0165","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-Cell maturation antigen chimeric antigen receptors for plasma cell malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0170","first-page":"134","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 for relapsed\/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial","author":"Li","year":"2019","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.critrevonc.2021.103453_bib0175","first-page":"686","article-title":"A phase 1 study of CT103A, a fully human bcma targeting car t cell, in subjects with relapsed\/refractory multiple myeloma","volume":"4","author":"Li","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0180","series-title":"G. BLENREP-Belantamab Injection, Powder, Lyophilized, for Solution: Highlights of Prescribing Information","author":"LLC","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0185","first-page":"136","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with Relapsed\/Refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103453_bib0195","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR t cell therapy in Relapsed\/Refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0205","first-page":"136","article-title":"Universal: an allogeneic first-in-human study of the anti-Bcma ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma","author":"Mailankody","year":"2020","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.critrevonc.2021.103453_bib0210","first-page":"418","article-title":"Orvacabtagene autoleucel (Orva-cel), A B-cell maturation antigen-directed car t cell therapy for patients with relapsed\/refractory multiple myeloma: update of the phase 1\/2 evolve study","volume":"4","author":"Mailankody","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0215","first-page":"1","article-title":"T cells expressing an Anti-B-Cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-Only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","author":"Mikkilineni","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103453_bib0220","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103453_bib0225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mcn.2014.01.002","article-title":"Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL","volume":"59","author":"Osorio","year":"2014","journal-title":"Mol. Cell. Neurosci."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2021.103453_bib0235","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting April for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2021.103453_bib0240","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","volume":"5","author":"Portell","year":"2013","journal-title":"Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103453_bib0245","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103453_bib0250","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139893","article-title":"Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-Cell redirecting antibody, in Relapsed\/Refractory multiple myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.critrevonc.2021.103453_bib0260","first-page":"61","article-title":"Idecabtagene vicleucel (IDE-CEL; BB2121), a BCMA-targeted car T cell therapy, in patients with relapsed and refractory multiple myeloma: initial karmma results","volume":"4","author":"San Miguel","year":"2020","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103453_bib0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11523-017-0538-x","article-title":"The role of B-Cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma","volume":"13","author":"Sanchez","year":"2018","journal-title":"Target. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103453_bib0270","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103453_bib0275","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0280","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor t cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103453_bib0285","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103453_bib0290","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103453_bib0295","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40035-017-0095-3","article-title":"Photophobia in neurologic disorders","volume":"6","author":"Wu","year":"2017","journal-title":"Transl. Neurodegener."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103453_bib0300","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:44Z","timestamp":1760902724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":60,"alternative-id":["S1040842821002419"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103453","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103453"}}